Brief: OSE Immunotherapeutics To Present New Preclinical Data At Bispecific Antibody And Immunology Conferences
19/10/2021 17:04
Oct 19 (Reuters) - Ose Immunotherapeutics SA OSE.PA :
* TO PRESENT NEW PRECLINICAL DATA AT UPCOMING BISPECIFIC
ANTIBODY
AND IMMUNOLOGY CONFERENCES
* PRESENTATIONS SHOW THAT T CELLS WHICH RECOGNIZE
NEOANTIGENS IN
HUMAN LUNG OR MELANOMA TUMORS POORLY EXPRESS IL-7R
* T CELLS WHICH RECOGNIZE NEOANTIGENS EXPRESS A HIGH LEVEL
OF PD-1
RECEPTORS
Source text for Eikon: ID:nGNXb9NzKp
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO